RxSight, Inc.

NasdaqGM RXST

RxSight, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 8.76

RxSight, Inc. Price to Sales Ratio (P/S) is 8.76 on January 14, 2025, a -49.49% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

RxSight, Inc. 52-week high Price to Sales Ratio (P/S) is 22.16 on February 27, 2024, which is 152.95% above the current Price to Sales Ratio (P/S).
RxSight, Inc. 52-week low Price to Sales Ratio (P/S) is 8.76 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
RxSight, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 16.55.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: RXST

RxSight, Inc.

CEO	Dr. Ronald M. Kurtz M.D.
IPO Date	July 30, 2021
Location	United States
Headquarters	100 Columbia
Employees	374
Sector	Consumer Discretionary
Industries Eyewear Cosmetics Pharmaceuticals

Description

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Key trends

Past 5 years